Difference between revisions of "Nedaplatin (Aqupla)"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "[http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or" to "or") |
||
| (5 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: A second-generation cisplatin | + | Class/mechanism: A second-generation cisplatin analog with antineoplastic activity. Containing a novel ring structure in which glycolate is bound to the platinum by a bidentate ligand, nedaplatin forms reactive platinum complexes that bind to nucelophillic groups in DNA, resulting in intrastrand and interstrand DNA cross-links, apoptosis and cell death. <ref>[https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=468844 NCI Drug Dictionary entry for nedaplatin]</ref> |
<br>Route: IV | <br>Route: IV | ||
<br>Extravasation: no information | <br>Extravasation: no information | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information. |
==Diseases for which it is used== | ==Diseases for which it is used== | ||
*[[Cervical cancer]] | *[[Cervical cancer]] | ||
| Line 14: | Line 14: | ||
*'''Generic name:''' nedaplat | *'''Generic name:''' nedaplat | ||
*'''Brand name:''' Aqupla, Jiebaishu | *'''Brand name:''' Aqupla, Jiebaishu | ||
| − | |||
| − | |||
==References== | ==References== | ||
<references /> | <references /> | ||
| Line 26: | Line 24: | ||
[[Category:Cervical cancer medications]] | [[Category:Cervical cancer medications]] | ||
[[Category:Nasopharyngeal carcinoma medications]] | [[Category:Nasopharyngeal carcinoma medications]] | ||
| − | + | [[Category:Non-small cell lung cancer medications]] | |
[[Category:Non-small cell lung cancer, squamous medications]] | [[Category:Non-small cell lung cancer, squamous medications]] | ||
[[Category:PMDA approved drugs]] | [[Category:PMDA approved drugs]] | ||
| − | [[Category:NMPA approved | + | [[Category:NMPA approved drugs]] |
Latest revision as of 00:10, 6 July 2024
General information
Class/mechanism: A second-generation cisplatin analog with antineoplastic activity. Containing a novel ring structure in which glycolate is bound to the platinum by a bidentate ligand, nedaplatin forms reactive platinum complexes that bind to nucelophillic groups in DNA, resulting in intrastrand and interstrand DNA cross-links, apoptosis and cell death. [1]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.
Diseases for which it is used
- Cervical cancer
- Nasopharyngeal carcinoma
- Non-small cell lung cancer, squamous
- Non-small cell lung cancer, EGFR-mutated
Also known as
- Code name: 254-S
- Generic name: nedaplat
- Brand name: Aqupla, Jiebaishu